Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Neurology

Disease Progression and Prognosis

At a Glance

Multiple System Atrophy, Cerebellar type (MSA-C) is a rapidly progressive condition with a median survival of 6 to 10 years after motor symptoms begin. Doctors track progression using the UMSARS scale, monitoring milestones like mobility changes, swallowing issues, and breathing difficulties.

Thinking about the future with Multiple System Atrophy, Cerebellar type (MSA-C) can be difficult. Because MSA-C is a “rapidly progressive” condition, the landscape of your health will change more quickly than it would with other neurodegenerative diseases like Parkinson’s [1]. However, understanding the typical milestones and “red flags” can help you and your family prepare and make informed decisions about your care.

The General Timeline

While every individual’s experience is unique, researchers have identified common patterns in how MSA-C unfolds. Most studies suggest a median survival of 6 to 10 years from the time motor symptoms first appear, but it is deeply important to remember that this is a statistical average [2][1]. Individual progression can vary widely. Proactive symptom management, a strong support system, and early palliative care can maximize the quality of the years ahead [3].

  • Mobility Milestones: Many patients find they need a walking aid (like a cane or walker) within 3 years of onset, and may transition to a wheelchair within 3 to 5 years to maintain safety [4][5].
  • Predictors of Speed: Progression tends to be faster in individuals who are older when symptoms first start [5].

Tracking Progress: The UMSARS Scale

Neurologists use a standardized tool called the Unified Multiple System Atrophy Rating Scale (UMSARS) to measure how the disease is moving [6].

  • What it Measures: The scale tracks everything from your ability to handle “activities of daily living” (like eating and dressing) to physical markers like coordination and speech [7][8].
  • What to Expect: On average, a patient’s total UMSARS score increases (worsens) by about 12 to 22 points each year [9][10]. Your doctor uses these numbers to decide when it might be time to adjust your medications or introduce new therapies.

Markers of Progression and Survival

Some symptoms act as “prognostic markers,” meaning they help doctors estimate the pace of the disease.

  • Early Dysphagia: If significant swallowing difficulties (dysphagia) begin within the first three years of the disease, it often predicts a shorter survival time [11][12]. This is because dysphagia increases the risk of aspiration pneumonia (food or liquid entering the lungs) [11].
  • Severe Autonomic Failure: Early and frequent falls—often caused by severe blood pressure drops—are also associated with a more aggressive course [13].

Late-Stage Complications to Watch For

As the disease reaches its more advanced stages, the focus of care often shifts toward preventing complications:

  • Respiratory Issues: Stridor (a high-pitched whistling sound when breathing in) can occur, especially during sleep. This indicates that the muscles in the throat are becoming uncoordinated and may require breathing support like a CPAP machine [14][15].
  • Recurrent Falls: Because balance and blood pressure regulation are both compromised, falls become a major risk for injury.
  • Infections: Pneumonia and urinary tract infections (UTIs) are the most common reasons for hospital stays in advanced MSA-C [11].

Choosing to involve palliative care early in the journey is not a sign of giving up; rather, it is a way to ensure that your symptoms—like pain, dizziness, and anxiety—are managed aggressively while you and your family plan for the road ahead [16].

Common questions in this guide

What is the typical life expectancy for someone with MSA-C?
Research suggests a median survival of 6 to 10 years from the time motor symptoms first appear. However, this is only a statistical average, and individual disease progression can vary widely depending on the person and their symptom management.
How fast does MSA-C progress?
MSA-C is a rapidly progressive condition. Many patients require a walking aid within three years of symptom onset and may transition to a wheelchair within three to five years to maintain safety. Progression tends to be faster in individuals who are older when symptoms begin.
What is the UMSARS scale used for in MSA-C?
Neurologists use the Unified Multiple System Atrophy Rating Scale (UMSARS) to track how the disease is progressing. It measures your ability to handle activities of daily living and physical markers like coordination, helping doctors decide when to adjust treatments.
Why are swallowing difficulties a concern in early MSA-C?
Significant swallowing difficulties, known as dysphagia, increase the risk of aspiration pneumonia, which happens when food or liquid accidentally enters the lungs. When this symptom begins early in the disease, doctors often use it as a marker to estimate a faster pace of disease progression.
What is stridor and why does it happen in late-stage MSA-C?
Stridor is a high-pitched whistling sound when breathing in, often occurring during sleep. It indicates that the muscles in the throat are becoming uncoordinated and may require the use of a breathing support device like a CPAP machine.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my current total score on the Unified Multiple System Atrophy Rating Scale (UMSARS), and how has it changed since my last visit?
  2. 2.How does the timing of my swallowing issues (dysphagia) affect your expectations for my care over the next few years?
  3. 3.At what point should we consider introducing a wheelchair or other mobility aids to prevent falls?
  4. 4.Are you seeing signs of 'stridor' or other respiratory complications that we need to address with a sleep study?
  5. 5.Can you help us start a conversation with a palliative care specialist to ensure my quality-of-life goals are met as the disease progresses?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (16)
  1. 1

    The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy.

    Wenning GK, Stankovic I, Vignatelli L, et al.

    Movement disorders : official journal of the Movement Disorder Society 2022; (37(6)):1131-1148 doi:10.1002/mds.29005.

    PMID: 35445419
  2. 2

    Epigallocatechin gallate in multiple system atrophy (PROMESA).

    Jellinger KA

    Annals of translational medicine 2019; (7(Suppl 8)):S278 doi:10.21037/atm.2019.11.141.

    PMID: 32015997
  3. 3

    Palliative Care Need and Quality of Life Mediated by Psychological Distress in Neurologic Diseases.

    Chan LML, Choi EPH, Lam WWT, et al.

    Journal of pain and symptom management 2025; (69(6)):641-653.e3 doi:10.1016/j.jpainsymman.2025.03.004.

    PMID: 40081623
  4. 4

    Screening for RFC-1 pathological expansion in late-onset ataxias: a contribution to the differential diagnosis.

    Barghigiani M, De Michele G, Tessa A, et al.

    Journal of neurology 2022; (269(10)):5431-5435 doi:10.1007/s00415-022-11192-x.

    PMID: 35633373
  5. 5

    Longitudinal study of a cohort of MSA-C patients in South Italy: survival and clinical features.

    Lieto M, Roca A, Bruzzese D, et al.

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2019; (40(10)):2105-2109 doi:10.1007/s10072-019-03948-7.

    PMID: 31152261
  6. 6

    Sensitivity to Change and Patient-Centricity of the Unified Multiple System Atrophy Rating Scale Items: A Data-Driven Analysis.

    Krismer F, Seppi K, Jönsson L, et al.

    Movement disorders : official journal of the Movement Disorder Society 2022; (37(7)):1425-1431 doi:10.1002/mds.28993.

    PMID: 35332582
  7. 7

    An Item Response Theory analysis of the Unified Multiple System Atrophy Rating Scale.

    Foubert-Samier A, Pavy-Le Traon A, Saulnier T, et al.

    Parkinsonism & related disorders 2022; (94()):40-44 doi:10.1016/j.parkreldis.2021.11.024.

    PMID: 34875563
  8. 8

    Natural history of multiple system atrophy in the USA: a prospective cohort study.

    Low PA, Reich SG, Jankovic J, et al.

    The Lancet. Neurology 2015; (14(7)):710-9.

    PMID: 26025783
  9. 9

    Longitudinal evolution of motor and non-motor symptoms in early-stage multiple system atrophy: a 2-year prospective cohort study.

    Zhang L, Hou Y, Cao B, et al.

    BMC medicine 2022; (20(1)):446 doi:10.1186/s12916-022-02645-1.

    PMID: 36397048
  10. 10

    Responsiveness of UMSARS and other clinical measures in a longitudinal structured care clinic for multiple system atrophy.

    Golden EP, McCreary M, Vernino S

    Clinical autonomic research : official journal of the Clinical Autonomic Research Society 2022; (32(6)):477-484 doi:10.1007/s10286-022-00898-7.

    PMID: 36181586
  11. 11

    Early-onset dysphagia predicts short survival in multiple system atrophy.

    Wada T, Shimizu T, Asano Y, et al.

    Journal of neurology 2024; (271(10)):6715-6723 doi:10.1007/s00415-024-12623-7.

    PMID: 39158732
  12. 12

    Endoscopic Characteristics of Dysphagia in Multiple System Atrophy Compared to Parkinson's Disease.

    Vogel A, Claus I, Ahring S, et al.

    Movement disorders : official journal of the Movement Disorder Society 2022; (37(3)):535-544 doi:10.1002/mds.28854.

    PMID: 34773420
  13. 13

    Disease progression and prognostic factors in multiple system atrophy: A prospective cohort study.

    Foubert-Samier A, Pavy-Le Traon A, Guillet F, et al.

    Neurobiology of disease 2020; (139()):104813 doi:10.1016/j.nbd.2020.104813.

    PMID: 32087288
  14. 14

    Heightened risk of early vocal fold motion impairment onset and dysphagia in the parkinsonian variant of multiple system atrophy: a comparative study.

    Tsuchiya K, Ueha R, Suzuki S, et al.

    Clinical parkinsonism & related disorders 2020; (3()):100037 doi:10.1016/j.prdoa.2020.100037.

    PMID: 34316623
  15. 15

    Swallowing Characteristics in Patients with Multiple System Atrophy Analyzed Using FEES Examination.

    Mozzanica F, Pizzorni N, Eplite A, et al.

    Dysphagia 2024; (39(3)):387-397 doi:10.1007/s00455-023-10619-5.

    PMID: 37733099
  16. 16

    Therapeutic Management of the Overlapping Syndromes of Atypical Parkinsonism.

    Giagkou N, Stamelou M

    CNS drugs 2018; (32(9)):827-837 doi:10.1007/s40263-018-0551-3.

    PMID: 30051337

This page provides educational information about MSA-C disease progression and prognosis. It is not a substitute for professional medical advice; always consult your neurologist regarding your specific timeline and care plan.

Get notified when new evidence is published on Multiple system atrophy, cerebellar type.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.